TY - JOUR
T1 - Application of polymeric nanoparticles for CNS targeted zinc delivery in vivo
AU - Chhabra, Resham
AU - Ruozi, Barbara
AU - Vilella, Antonietta
AU - Belletti, Daniela
AU - Mangus, Katharina
AU - Pfaender, Stefanie
AU - Sarowar, Tasnuva
AU - Boeckers, Tobias Maria
AU - Zoli, Michele
AU - Forni, Flavio
AU - Vandelli, Maria Angela
AU - Tosi, Giovanni
AU - Grabrucker, Andreas Martin
N1 - Publisher Copyright:
© 2015 Bentham Science Publishers.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - A dyshomeostasis of zinc ions has been reported for many psychiatric and neurodegenerative disorders including schizophrenia, attention deficit hyperactivity disorder, depression, autism, Parkinson’s and Alzheimer’s disease. Furthermore, alterations in zinc-levels have been associated with seizures and traumatic brain injury. Thus, altering zinclevels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. However, given the restriction of zinc uptake into the brain by the blood-brain barrier, methods for controlled regulation and manipulation of zinc concentrations within the brain are rare. Here, we performed in vivo studies investigating the possibility of brain targeted zinc delivery using zinc-loaded nanoparticles which are able to cross the blood-brain barrier. After injecting these nanoparticles, we analyzed the regional and time-dependent distribution of zinc and nanoparticles within the brain. Moreover, we evaluated whether the presence of zinc-loaded nanoparticles alters the expression of zinc sensitive genes and proteins such as metallothioneins and zinc transporters and quantified possible toxic effects. Our results show that zinc loaded g7 nanoparticles offer a promising approach as a novel non - invasive method to selectively enrich zinc in the brain within a small amount of time.
AB - A dyshomeostasis of zinc ions has been reported for many psychiatric and neurodegenerative disorders including schizophrenia, attention deficit hyperactivity disorder, depression, autism, Parkinson’s and Alzheimer’s disease. Furthermore, alterations in zinc-levels have been associated with seizures and traumatic brain injury. Thus, altering zinclevels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. However, given the restriction of zinc uptake into the brain by the blood-brain barrier, methods for controlled regulation and manipulation of zinc concentrations within the brain are rare. Here, we performed in vivo studies investigating the possibility of brain targeted zinc delivery using zinc-loaded nanoparticles which are able to cross the blood-brain barrier. After injecting these nanoparticles, we analyzed the regional and time-dependent distribution of zinc and nanoparticles within the brain. Moreover, we evaluated whether the presence of zinc-loaded nanoparticles alters the expression of zinc sensitive genes and proteins such as metallothioneins and zinc transporters and quantified possible toxic effects. Our results show that zinc loaded g7 nanoparticles offer a promising approach as a novel non - invasive method to selectively enrich zinc in the brain within a small amount of time.
KW - Blood brain barrier
KW - Brain
KW - drug delivery
KW - Nanoparticle (NP)
KW - Poly(D,L-lactide-co-glycolide) (PLGA)
KW - Zn
KW - ZnSO
UR - http://www.scopus.com/inward/record.url?scp=84945425160&partnerID=8YFLogxK
U2 - 10.2174/1871527314666150821111455
DO - 10.2174/1871527314666150821111455
M3 - Article
C2 - 26295815
AN - SCOPUS:84945425160
SN - 1871-5273
VL - 14
SP - 1041
EP - 1053
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 8
ER -